Drug Trial Radar · NCT05600894
Venetoclax in Combination With ASTX727 for the Treatment of Chronic Myelomonocytic Leukemia and Other Myelodysplastic Syndrome/Myeloproliferative Neoplasm
Last checked: Nov 20, 2026Latest source record: Aug 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
132
Planned (sponsor's estimate)
Start
Jun 27, 2023
Primary completion
Aug 31, 2027
Study completion Aug 31, 2027
Sponsor
- Lead sponsor
- National Cancer Institute (NCI)NIH
- Sponsor type
- NIH
- First posted
- Nov 1, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Crossover
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This phase II trial tests whether decitabine and cedazuridine (ASTX727) in combination with venetoclax work better than ASTX727 alone at decreasing symptoms of bone marrow cancer in patients with chronic myelomonocytic leukemia (CMML), myelodysplastic syndrome/myeloproliferative neoplasm (MDS/MPN) with excess blasts. Blasts are immature blood cells. Decitabine is in a class of medications called hypomethylation agents. It works by helping the bone marrow produce normal blood cells and by killing abnormal cells in the bone marrow. Cedazuridine is in a class of medications called cytidine deaminase inhibitors. It prevents the breakdown of decitabine, making it more available in the body so that decitabine will have a greater effect. Venetoclax is in a class of medications called B-cell lymphoma-2 (BCL-2) inhibitors. It may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. The combination of ASTX727 and venetoclax may be more effective in reducing the cancer signs and symptoms in patients with CMML, or MDS/MPN with excess blasts.
Conditions
- Chronic Myelomonocytic Leukemia
- Myelodysplastic Syndrome
- Myelodysplastic Syndrome With Excess Blasts
- Myelodysplastic/Myeloproliferative Neoplasm
- Myeloproliferative Neoplasm
Interventions
Biospecimen CollectionProcedure
Undergo collection of blood and buccal samples
Bone Marrow AspirationProcedure
Undergo bone marrow aspiration
Bone Marrow BiopsyProcedure
Undergo bone marrow biopsy
Decitabine and CedazuridineDrug
Given PO
VenetoclaxDrug
Given PO
Primary outcomes
What the sponsor says the trial is designed to measure.
- Complete response rateTime frame: Up to 4 cycles
Locations
34 sites in 2 countries. Site status is shown where the registry gives one.
Mayo Clinic Hospital in Arizona
Phoenix, Arizona
UC Irvine Health Cancer Center-Newport
Costa Mesa, California
UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care
Irvine, California
UCI Health Laguna Hills
Laguna Hills, California
Los Angeles General Medical Center
Los Angeles, California
USC / Norris Comprehensive Cancer Center
Los Angeles, California
UC Irvine Health/Chao Family Comprehensive Cancer Center
Orange, California
University of California Davis Comprehensive Cancer Center
Sacramento, California
Yale University
New Haven, Connecticut
Mayo Clinic in Florida
Jacksonville, Florida
Northwestern University
Chicago, Illinois
University of Chicago Comprehensive Cancer Center
Chicago, Illinois
UC Comprehensive Cancer Center at Silver Cross
New Lenox, Illinois
University of Chicago Medicine-Orland Park
Orland Park, Illinois
University of Kansas Cancer Center
Kansas City, Kansas
University of Kansas Hospital-Westwood Cancer Center
Westwood, Kansas
University of Maryland/Greenebaum Cancer Center
Baltimore, Maryland
Johns Hopkins University/Sidney Kimmel Cancer Center
Baltimore, Maryland
Beth Israel Deaconess Medical Center
Boston, Massachusetts
NYP/Weill Cornell Medical Center
New York, New York
Montefiore Medical Center-Einstein Campus
The Bronx, New York
Montefiore Medical Center-Weiler Hospital
The Bronx, New York
Montefiore Medical Center - Moses Campus
The Bronx, New York
UNC Lineberger Comprehensive Cancer Center
Chapel Hill, North Carolina
Wake Forest University Health Sciences
Winston-Salem, North Carolina
University of Cincinnati Cancer Center-UC Medical Center
Cincinnati, Ohio
Ohio State University Comprehensive Cancer Center
Columbus, Ohio
University of Cincinnati Cancer Center-West Chester
West Chester, Ohio
University of Oklahoma Health Sciences Center
Oklahoma City, Oklahoma
UPMC Hillman Cancer Center
Pittsburgh, Pennsylvania
Huntsman Cancer Institute/University of Utah
Salt Lake City, Utah
University of Virginia Cancer Center
Charlottesville, Virginia
VCU Massey Comprehensive Cancer Center
Richmond, Virginia
University Health Network-Princess Margaret Hospital
Toronto, Ontario, Canada
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.